Suppr超能文献

BIGH3在肾透明细胞癌中过表达。

BIGH3 is overexpressed in clear cell renal cell carcinoma.

作者信息

Yamanaka Masanori, Kimura Fumihiro, Kagata Yutaka, Kondoh Nobuo, Asano Tomohiko, Yamamoto Mikio, Hayakawa Masamichi

机构信息

Department of Urology, National Defense Medical College, Saitama 359-8513, Japan.

出版信息

Oncol Rep. 2008 Apr;19(4):865-74.

Abstract

To identify new target marker genes in renal cell carcinoma (RCC), we compared the gene expression profiles of clear cell RCC (cc-RCC) and normal kidney tissue using serial analysis of gene expression. Our results revealed that the transforming growth factor beta induced 68 kDa protein (TGF-betaI: beta ig-h3 (BIGH3), plasminogen activator inhibitor-1 (PAI-1) and transforming growth factor beta1 (TGF-beta1) genes are up-regulated in cc-RCC. To further assess the role of BIGH3 in RCC, we investigated the mRNA expression levels of BIGH3, TGFbeta1, PAI-1 and also of TGF-beta1 related genes in 53 RCC and 30 normal kidney tissues by quantitative real-time RT-PCR (QRT-PCR). We further determined the BIGH3 protein levels in 52 cc-RCC paraffin-embedded tissue samples by immunohistochemistry. BIGH3 mRNA was found to be highly overexpressed in cc-RCC compared with normal tissues with an average ratio of 27. The mRNA levels of TGF-beta1 and PAI-1 were also detected at significantly elevated levels in these cancers. Immunohistochemical analysis of BIGH3 also revealed strong staining in the majority of the cc-RCC samples. In addition, the up-regulation of BIGH3 and PAI-1 was found to correlate with the clinicopathological parameters associated with a poorer patient outcome, whereas TGF-beta1 expression was determined to be unrelated to cancer progression. Strong BIGH3 staining thus tended to be associated with a poor prognosis. BIGH3 was also induced in some RCC cell lines by TGF-beta1 stimulation and this correlated well with PAI-1 up-regulation, suggesting that these enhancements are regulated by a similar mechanism in these tumors.

摘要

为了鉴定肾细胞癌(RCC)中的新靶标标记基因,我们使用基因表达序列分析比较了透明细胞RCC(cc-RCC)和正常肾组织的基因表达谱。我们的结果显示,转化生长因子β诱导的68 kDa蛋白(TGF-βI:βig-h3(BIGH3)、纤溶酶原激活物抑制剂-1(PAI-1)和转化生长因子β1(TGF-β1)基因在cc-RCC中上调。为了进一步评估BIGH3在RCC中的作用,我们通过定量实时RT-PCR(QRT-PCR)研究了53例RCC和30例正常肾组织中BIGH3、TGFβ1、PAI-1以及TGF-β1相关基因的mRNA表达水平。我们还通过免疫组织化学测定了52例cc-RCC石蜡包埋组织样本中的BIGH3蛋白水平。与正常组织相比,发现cc-RCC中BIGH3 mRNA高度过表达,平均比值为27。在这些癌症中也检测到TGF-β1和PAI-1的mRNA水平显著升高。BIGH3的免疫组织化学分析还显示,大多数cc-RCC样本中有强染色。此外,发现BIGH3和PAI-1的上调与患者预后较差相关的临床病理参数相关,而TGF-β1表达与癌症进展无关。因此,强BIGH3染色往往与预后不良相关。TGF-β1刺激也在一些RCC细胞系中诱导了BIGH3,这与PAI-1上调密切相关,表明这些增强在这些肿瘤中受类似机制调控。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验